BioSpace News Archive

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 30,400 shares of the Company’s common stock at an exercise price per share of $28.24, which was the closing price on August 9, 2021.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Conyers, Georgia.

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress.

New research has revealed a significant reduction in the need for total hip and knee replacement surgery among rheumatoid arthritis patients after the introduction of biologics.

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and GT Molecular, a leader in providing customizable, highly sensitive digital PCR and qPCR tests based in the U.S., have started to offer a complete wastewater workflow solution designed to enable surveillance of COVID-19 outbreaks by U.S. and Canadian laboratories, with future options to offer the solution in other countries.

Mirum Pharmaceuticals, Inc. announced that on August 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,200 shares of common stock to eight new employees under Mirum’s 2020 Inducement Plan.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting phase II clinical trial in primary immune thrombocytopenia (ITP) in China.

Intercept Pharmaceuticals, Inc. announced that it has entered into privately negotiated agreements with certain of the holders of its existing 3.25% Convertible Senior Notes due 2023 and 2.00% Convertible Senior Notes due 2026 to exchange an aggregate of $306.5 million principal amount of 2023 Notes and an aggregate of $114.7 million principal amount of 2026 Notes for a newly issued series of Convertible Senior Secured Notes due 2026.